VIT-2763

• Description :

  VIT-2763, an oral ferroportin inhibitor, inhibits hepcidin binding to ferroportin and blocks iron efflux. VIT-2763 has the potential in the treatment of β-thalassemia[1].

• UNSPSC :

  12352005

• Target :

  Ferroportin; Hepcidin

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/vit-2763.html

• Purity :

  99.93

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=COC(CCNCCC2=NC3=CC=CC=C3N2)=N1)NCC4=NC=CC=C4F

• Molecular Formula :

  C21H21FN6O2

• Molecular Weight :

  408.43

• References & Citations :

  [1]Vania Manolova, et al. Oral Ferroportin Inhibitor Ameliorates Ineffective Erythropoiesis in a Model of β-Thalassemia. J Clin Invest. 2019 Dec 9;130 (1) :491-506.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [2095668-10-1]